Skip to main content

ExonHit Gains Dx Commercialization Rights Under Modified Deal with bioMerieux

NEW YORK (GenomeWeb News) - ExonHit Therapeutics said today that it has amended its longstanding partnership with bioMerieux in order to gain commercial rights to cancer diagnostic kits developed through the agreement.
 
The amended agreement also gives bioMerieux “greater flexibility to initiate new research and development projects in that field,” ExonHit said.
 
The partnership began in 2003 to develop breast cancer diagnostics and was expanded in 2005 to include other types of cancers, including colon, prostate, and lung.
 
The goal of the partnership is to develop DNA microarrays to detect cancer markers in blood samples. ExonHit is providing its gene expression analysis know-how and intellectual property, and on bioMerieux is contributing its knowledge of in vitro diagnostics.
 
The companies are currently working on three programs: breast cancer, colorectal cancer, and prostate cancer.
 
Terms of the previous agreement gave bioMérieux an exclusive license to ExonHit’s technology and methods in the field of blood diagnostics, gene profiling, and microarray design. In exchange, bioMérieux covered ExonHit's R&D costs and provided milestone payments.
 
The new agreement will allow ExonHit to market the diagnostic kits developed through the partnership to pharmaceutical companies or to hospitals taking part in clinical studies, “in order to help them recruit patients for their clinical studies.”
 
Bruno Tocque, chairman of ExonHit’s management board, called the amendment “a major step forward in ExonHit's development because it allows us to consider generating our own source of revenues from products based on our technology which are issued from the collaboration."

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.